Annual Meeting Proceedings - American Academy of Orthopaedic ...

More documents

Recommendations

Info

NAME DISCLOSURE NAME DISCLOSURE Daniel Mole, MD 1 – Tornier Massimo Molinari, MD .....................................................n Ryan Molli, DO ............................................................n Anne Molloy, RN ..........................................................n Robert M Molloy, MD 5 – Stryker Shigeki Momohara 2 – Abbott, Pfizer, Wyeth, Astellas Pharma, Chugai, Eisai, Kaken Pharmaceutical, Mitsubishi Tanabe, Santen, Bristol-Myers Squibb; 3B – Zimmer, Bristol- Myers Squibb Keith Oster Monchik, MD 3B – Depuy Mitek, Symmetry Medical, Smith & Nephew; 5 – Stryker James T Monica, MD .......................................................n Andrew P Monk, MRCS .....................................................n Michael A Mont, MD 1 – Stryker; 3B – Stryker, Wright Medical Technology, Inc.; 5 – National Institutes of Health (NIAMS & NICHD), Stryker, Tissue Gene, Wright Medical Technology, Inc. Antonello Montanaro, MD ..................................................n Aldo Campusano Montaño .................................................n Martim Teixiera Monteiro, MD ...............................................n Pasquale X Montesano, MD 1 – Scient’x, Spinal USA; 4 – Cytonics Park Moon Seok, MD .......................................................n Bryan Scott Moon, MD .....................................................n Kyoung Ho Moon, MD 2 – DePuy, A Johnson & Johnson Company, Korea Bone Bank; 3C, 4, 5 – Korea Bone Bank Young-Wan Moon, MD .....................................................n James F Mooney III, MD 3B – Synthes Spine Molly Moor ...............................................................n Andrew M Moore, MD ......................................................n Drew Douglas Moore, MD ..................................................n Claude T Moorman III, MD 2 – Nutramax Corp.; 3B – Smith & Nephew; 4 – Healthsport; 5 – Stryker, Histogenics, Breg, Mitek, DJ Orthopaedics, Arthrex Claudio Moraga, MD .......................................................n Luis Moraleda, MD .........................................................n Raymond Moran, FRCS .....................................................n Steven L Moran, MD 1, 2 – Ascension Lawrence G Morawa, MD 1, 3B – Stryker Dan Morell, MBBS, BS ......................................................n Vincent Michael Moretti, MD ................................................n Dr Joseph A Morgan .......................................................n Eiji Mori, MD .............................................................n Mario Moric, MS ...........................................................n Ryo Morimoto, MD ........................................................n Tetsuro Morita, MD ........................................................n Deml Moritz, MD ..........................................................n Tokuhide Moriyama, MD ...................................................n Antonio Moroni, MD 2, 3B, 4 – Active Implants; 7 – Orthofix Edward Morra, MSME ......................................................n Bernard F Morrey, MD 1 – SBI, Don Joy; 3B – Zimmer; 7 – Wolters Kluwer Health - Lippincott Williams & Wilkins, Elsevier Brent J Morris, MD .........................................................n Carol D Morris, MD ........................................................n Michael James Morris, MD 5 – Biomet Carol Morrison, PhD .......................................................n William B Morrison, MD 1, 3C – Apriomed, Inc.; 2 , 3B – General Electric Medical Systems; 7 – Elsevier, Amirsys Melanie Morscher ..........................................................n Saam Morshed, MD 5 – Stryker, Synthes S M Javad Mortazavi, MD ...................................................n Anne Morton, PhD .........................................................n Vincent Stephen Mosca, MD .................................................n Colin F Moseley, MD 3C – Orthopaediatrics Rami Mosheiff, MD ........................................................n Timothy J Mosher MD 3B – Kensey Nash Corporation; 4 – Johnson & Johnson Mathew Most, MD 5 – DePuy, A Johnson & Johnson Company Richard A Mostardi, PhD 5 – Zimmer, Astro Met John Motley, PT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .n Michael P Mott, MD 4 – Johnson & Johnson; 5 – GE Healthcare 50 disclosure Geraldo Motta, MD ........................................................n Calin Stefan Moucha, MD ...................................................n Loran Mounir-Soliman, MD .................................................n Waleed Fouad Mourad, MD .................................................n Alexandre Mouttet, MD .....................................................n Vasilios Moutzouros, MD ...................................................n Petter Mowinckel, PhD .....................................................n Luis Emilio Moya , MD .....................................................n Kyle C Moylan, MD ........................................................n Thomas Edward Mroz, MD 2 – Stryker; 4 – PearlDiver, Inc. Scott J Mubarak, MD 4, 6 – Rhino Pediatric Orthopedic Designs, Inc. Chaitanya S Mudgal, MD ...................................................n John P Mueller, PhD 6 – Medtronic, DePuy, A Johnson & Johnson Company, Wright Medical Technology, Inc. Sarah Muirhead-Allwood FRCS 1, 3B – DePuy, A Johnson & Johnson Company, Zimmer, Corin U.S.A.; 5 – Zimmer Debi P Mukherjee, Sc.D .....................................................n Kevin James Mulhall, MD ...................................................n Scott Muller, MBBS MD, FRCS ...............................................n Brian Mullis, MD 5 – Amgen Co., Synthes Kishore Mulpuri, MD .......................................................n Gregory M Mundis, MD 2 – Nuvasive, K2M; 3B – K2M, Nuvasive; 5 – Nuvasive, DePuy, A Johnson & Johnson Company, OREF Joel Murachovsky, MD ......................................................n Akira Murakami, MD .......................................................n Hideki Murakami, MD .....................................................n Orhun K Muratoglu, PhD 1 – Biomet, Zimmer, Corin U.S.A.; 2, 3C – Biomet; 5 – Biomet, Zimmer, MAKO, DePuy Christopher D Murawski ....................................................n Professor Antonio Murcia Asensio ...........................................n Antonio Murcia-Mazon, MD .................................................n Garnett Andrew Murphy, MD 3C – Wright Medical Technology, Inc.; 5 – BioMimetic; 7 – Saunders/Mosby-Elsevier James Murphy, MD .........................................................n Stephen B Murphy, MD 1 – Wright Medical Technology, Inc.; 3B – Wright Medical Technology, Inc., Ceramtec, AG; 4 – Surgical Planning Associates, Inc. Clint Murray, MD ..........................................................n David W Murray, MD 1 – Biomet, Wright Medical Technology, Inc.; 5 – Biomet, DePuy, A Johnson & Johnson Company, Stryker, Zimmer, Wright Medical Technology, Inc. Douglas H Murray, MD 3C – Exactech, Inc. Martha M Murray, MD 3B, 4 – Connective Orthopaedics Michael R Murray, MD ......................................................n Paraic A Murray, MD .......................................................n Trevor G Murray, MD .......................................................n Prof George A C Murrell, MD 5 – Arthrocare Yvonne M Murtha, MD .....................................................n Anand M Murthi, MD 3B – Zimmer, Ascension A N Murty, MBcHB, FRCS ...................................................n Volker Musahl, MD ........................................................n Dana Lynn Musapatika, MS .................................................n George F Muschler, MD 4 – Cleveland Biolabs; 5 – Synthes, Procter & Gamble Domingo Luis Muscolo, MD ................................................n Mrinal Musib, PhD .........................................................n Gregory Donald Myer, PhD .................................................n Andy Myerson, PA-C 4 – Wright Medical Technology, Inc.; 6 – Ocean Surgical Inc. Mark S Myerson, MD 1 – Biomet, DePuy, A Johnson & Johnson Company; 2 – Biomet, DePuy, A Johnson & Johnson Company, Orthohelix; 3B – Biomet, DePuy, A Johnson & Johnson Company, Medtronic, Stryker, Tornier, Orthohelix, Extremity Medical; 3C – Medtronic; 4 – Orthohelix; 5 – Biomet, OREF, Allosource; 7 – Elsevier Valentin Myrtille, MS .......................................................n Karen Myung, MD .........................................................n Colin Nabb, BS ............................................................n Matthew C Nadaud, MD ....................................................n Dr Mohammad Nasir Naderi ................................................n Yuko Nagaya, MD ..........................................................n Daniel J Nagle, MD ........................................................n The codes after the name are identified as 1 – Royalties; 2 – Speakers Bureau/paid presentations, 3a. – Employee, 3b. – Paid consultant, 3c. – Unpaid consultant, 4 – Stock or stock options; 5 – Research or institutional support as a principal investigator has been received; 6 – Other financial or material support;7 - Royalties, financial or material support from publishers; n – No conflicts to disclose. For full information refer to page 19.
NAME DISCLOSURE NAME DISCLOSURE Satoshi Nagoya, MD ........................................................n Lakshmi Sreedharan Nair, PhD 3C, 4 – Soft Tissue Regeneration Masatoshi Naito, MD .......................................................n Ichiro Nakahara ...........................................................n Hiroaki Nakamura, MD .....................................................n Junichi Nakamura, MD .....................................................n Nobuo Nakamura, MD .....................................................n Takashi Nakamura, MD .....................................................n Takuya Nakamura, MD 2 – Zimmer, Lima; 3B – Zimmer; 5 – JMM Yoshinari Nakamura, MD ...................................................n Yuko Nakashima, MD ......................................................n Katsuya Nakata, MD 5 – Corin; 6 – Corin Japan Amgad Ihab Nakhla, MSc, FRCS .............................................n Ufuk Nalbantoglu, MD .....................................................n Denis Nam, MD ...........................................................n Kwang Woo Nam, MD ......................................................n Robert S Namba, MD 1 – Innomed; 7 – Mc Graw Hill Surena Namdari, MD, MSc ..................................................n Chaitanya Nandipati, BS ....................................................n Matteo Nanni, MD .........................................................n Robert J. Napleton, JD ......................................................n Antoni Nargol, FRCS .......................................................n Jason Warren Nascone, MD 3B – Synthes Adam Nasreddine, BS ......................................................n Rima Nasser, MD ..........................................................n Ahmad Nassr, MD .........................................................n Sonali Natu, MD ...........................................................n Doug Naudie, MD 1 – Smith & Nephew; 2, 3B – Smith & Nephew, Stryker; 5 – Smith & Nephew, DePuy, A Johnson & Johnson Company, Stryker Aaron Nauth, MD ..........................................................n Ronald Anthony Navarro, MD ...............................................n Syed Nawaz, MRCS .........................................................n Tariq Ali Nayfeh, MD 3B – Smith & Nephew Samir Nayyar, MD .........................................................n Ara Nazarian ..............................................................n Qais Naziri, MD ...........................................................n Deborah R Neal, BS ........................................................n Stefan Nehrer, MD 5 – Arthro Kinetics, Chroma Pharma Michael John Neil, MD 2, 5 – DePuy, A Johnson & Johnson Company; 3B – Global Orthopaedic Technology Geraldine Neiss, PhD .......................................................n Rob G H H Nelissen, MD 3C – Biomet, Synthes, Stryker, BroadVector, Implantcast; 5 – Stryker, Biomet, Synthes, Implantcast Kate W Nellans, MD ........................................................n Andrea Nelson, ATC, OTC ...................................................n Charles L Nelson, MD 3B – Zimmer Christopher D Nelson, DO ..................................................n David L Nelson, MD 1, 3B, 4, 6 – Orthofix, Inc.; 2 – Orthofix, Inc., Synthes Eric W Nelson, MD .........................................................n Fred R T Nelson, MD 7 – Elsevier Sandra Bliss Nelson, MD 4 – Abbott, Johnson & Johnson, Hospira, Biogen Scott C Nelson, MD ........................................................n Scott Nemec, DO ..........................................................n Jeffrey Nepple, MD .........................................................n Bryan J Nestor, MD .........................................................n Philip R Neubauer, MD 3A, 4 – Celgene Brian J Neuman, MD .......................................................n Adam Z Neustein, BS .......................................................n Enrico Neven, MD .........................................................n Claire Newell, BSc .........................................................n Drew K Newhoff, BA 4 – Stryker Ms Lori Newman ..........................................................n Peter O Newton, MD 1, 2, 3B – DePuy, A Johnson & Johnson Company; 3C – Stryker; 4 – Nuvasive; 5 – DePuy, A Johnson & Johnson Company, Axial Biotech, Biospace Med; 7 – Thieme Publishing 51 disclosure Lionel Neyton, MD 3B – Tornier, Mitek Aaron Ng, MD .............................................................n Cho Ng, MBBS ............................................................n Vincent Ng, MD ...........................................................n Mthunzi Ngcelwane, MD ....................................................n Trung Ngo, DC ............................................................n Dat Nguyen, PharmD 3A, 3B, 4 – Auxilium Pharmaceuticals Ngoc Quyen Nguyen, MD ...................................................n Sang-Eun Nha, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .n Shane Nho, MD 5 – Arthrex, Inc., Linvatec, Smith & Nephew, DJ Orthopaedics, Miomed, Athletico Yoon-Mi Nho ..............................................................n Christophe Nich, MD 5 – Osteotech Alexander S Nicholls .......................................................n David P Nicholls, PhD ......................................................n Gregory P Nicholson, MD 1 – Innomed, Zimmer; 3B, 4 – Zimmer; 5 – EBI, Tornier, Zimmer; 7 – SLACK Incorporated Florian Nickisch, MD 2, 3B – Smith & Nephew Kathie Niesen .............................................................n Marc J Nieuwenhuijse, MD ..................................................n Marco Nigrisoli, MD .......................................................n Vassilios Nikolaou, MD .....................................................n James T Ninomiya, MD .....................................................n Lana Nirenstein, MSII ......................................................n Hideji Nishida, MD ........................................................n Takashi Nishii, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .n Carl Wilson Nissen, MD 2 – Genzyme Lorenzo Nistri, MD ........................................................n Marco Nitri, MD ...........................................................n Philip C Noble, PhD 1 – Zimmer, Stryker, Smith & Nephew; 2 – Smith & Nephew; 3B – Smith & Nephew, Zimmer; 5 – Synthes, Zimmer; 6 – Musculoskeletal Transplant Foundation, Zimmer, Plus Orthopedics Ulrich Noeth ..............................................................n Michael M Nogler, MD 2, 3B – Stryker; 5 – Stryker, Heraeus; 7 – Springer Monica Paschoal Nogueira, MD ..............................................n Won Noh, MD .............................................................n Rahime Nohutcu, DT .......................................................n Dr Elizabeth M Nolan ......................................................n Lutz P Nolte, PhD ..........................................................n Tomohiro Nomura, MD ....................................................n Ken J Noonan, MD 1, 3B, 5 – Biomet Vanessa Noonan, PhD ......................................................n Robert L Nora, JD ..........................................................n Sean E Nork, MD 2 – Synthes, AONA; 3B – Synthes, AONA, Amgen; 5 – Synthes, AONA, OTA Masoud Norouzi ...........................................................n Casey Northam, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .n Mark Norton, MD 3C – Corin UK Tom F Novacheck, MD ......................................................n Eduardo Nilo Novais, MD ...................................................n Jenna B Noveau, BS ........................................................n Wendy Novicoff, PhD 3B – Exactech, Inc., Smith & Nephew Robert J Nowinski, DO 2 – Tornier; 3B – Tornier, Renovis; 5 – Tornier, Lifecell Frank R Noyes, MD 1 – Smith & Nephew; 2 – Genzyme; 6 – Arthrex, Inc., DePuy- Mitek, Regeneration Technologies, Inc., AlloSource; 7 – Saunders/Mosby-Elsevier Masahiro Nozaki, MD ......................................................n Akosua A Nti, BA ..........................................................n Gordon W Nuber, MD 4 – Johnson & Johnson, Stryker; 5 – Sage Pharmaceuticals Syam Prasad Nukavarapu, PhD ..............................................n James Albert Nunley II, MD 1 – Wright Medical Technology, Inc.; 3B – SBI, Smith & Nephew, Stryker, Wright Medical Technology, Inc., Integra Lifesciences; 4 – Bristol-Myers Squibb, Merck, Johnson & Johnson; 5 – Biomet, EBI, OREF, Pfizer, Synthes, DePuy, A Johnson & Johnson Company, Arthrex, Inc.; 7 – Springer, Datatrace Ryan Nunley, MD 3B – Smith & Nephew, Wright Medical Technology, Inc., Salient Surgical; 5 – Biomet, Wright Medical Technology, Inc., Stryker, Smith & Nephew, Biospace, Mobile Compression Systems The codes after the name are identified as 1 – Royalties; 2 – Speakers Bureau/paid presentations, 3a. – Employee, 3b. – Paid consultant, 3c. – Unpaid consultant, 4 – Stock or stock options; 5 – Research or institutional support as a principal investigator has been received; 6 – Other financial or material support;7 - Royalties, financial or material support from publishers; n – No conflicts to disclose. For full information refer to page 19.
Page 1 and 2: AAOS 2011 A N N U A L M E E T I N G
Page 3 and 4: Subspecialty Guide to the Annual Me
Page 5 and 6: 5 Scientific Posters 1:00 PM-6:00 P
Page 7 and 8: 7 Symposia Scientific Exhibits 7:00
Page 9 and 10: 9 Scientific Posters 7:00 AM-6:00 P
Page 11 and 12: ReHABilitAtion Scientific Papers sH
Page 13 and 14: 13 ReHABilitAtion Specialty Day sHo
Page 15 and 16: 15 Start here to begin your partici
Page 17 and 18: SPORTS MEDICINE/ARTHROSCOPy (Cont.)
Page 19 and 20: NAME DISCLOSURE NAME DISCLOSURE NAM
Page 21 and 22: NAME DISCLOSURE NAME DISCLOSURE Gor
Page 23 and 24: NAME DISCLOSURE NAME DISCLOSURE 23
Page 25 and 26: NAME DISCLOSURE NAME DISCLOSURE Ki-
Page 27 and 28: NAME DISCLOSURE NAME DISCLOSURE Rob
Page 29 and 30: NAME DISCLOSURE NAME DISCLOSURE Eug
Page 31 and 32: NAME DISCLOSURE NAME DISCLOSURE Ete
Page 33 and 34: NAME DISCLOSURE NAME DISCLOSURE Sep
Page 35 and 36: NAME DISCLOSURE NAME DISCLOSURE Li
Page 37 and 38: NAME DISCLOSURE NAME DISCLOSURE Ric
Page 39 and 40: NAME DISCLOSURE NAME DISCLOSURE Dav
Page 41 and 42: NAME DISCLOSURE NAME DISCLOSURE Mar
Page 43 and 44: NAME DISCLOSURE NAME DISCLOSURE Dan
Page 45 and 46: NAME DISCLOSURE NAME DISCLOSURE Sam
Page 47 and 48: NAME DISCLOSURE NAME DISCLOSURE Sco
Page 49: NAME DISCLOSURE NAME DISCLOSURE Tho
Page 53 and 54: NAME DISCLOSURE NAME DISCLOSURE Pao
Page 55 and 56: NAME DISCLOSURE NAME DISCLOSURE Pau
Page 57 and 58: NAME DISCLOSURE NAME DISCLOSURE Kaz
Page 59 and 60: NAME DISCLOSURE NAME DISCLOSURE Ani
Page 61 and 62: NAME DISCLOSURE NAME DISCLOSURE Nob
Page 63 and 64: NAME DISCLOSURE NAME DISCLOSURE Tak
Page 65 and 66: NAME DISCLOSURE NAME DISCLOSURE Ste
Page 67 and 68: NAME DISCLOSURE NAME DISCLOSURE Li
Page 69 and 70: 69 New FroNtierS iN Cartilage imagi
Page 71 and 72: 71 relatioNShipS betweeN imagiNg Si
Page 73 and 74: 73 neck offset a acetabular rim fra
Page 75 and 76: In summary, joint preserving hip su
Page 77 and 78: SELECTED READINGS: 1. Blumenkrantz,
Page 79 and 80: 79 highly CroSSliNked polyethyleNe:
Page 81 and 82: 81 metal oN metal: low wear aNd Sta
Page 83 and 84: 83 doeS hip reSurFaCiNg have a role
Page 85 and 86: xvi. Della Valle CF, Nunley RM, Rat
Page 87 and 88: 3. Surgical learning curve remains
Page 89 and 90: Rogmark et al. (2003): Costs 2 Year
Page 91 and 92: REFERENCES: 1. U.S. Census Bureau.
Page 93 and 94: 93 high FleXioN iN tka : teChNology
Page 95 and 96: 95 review of 100 cases with Durasul
Page 97 and 98: REFERENCES: 97 Results of a randomi
Page 99 and 100: 99 why i reSurFaCe all patellae iN
Page 101 and 102:
101 JoiNt preServatioN hip Surgery:
Page 103 and 104:
103 — Hyperextension — Lumbar S
Page 105 and 106:
105 periaCetabular oSteotomy: avoid
Page 107 and 108:
107 SurgiCal diSloCatioN oF the hip
Page 109 and 110:
109 - • ITB / Gracilis / Ligament
Page 111 and 112:
with concomitant removal of hardwar
Page 113 and 114:
113 diSloCatioN aFter total hip art
Page 115 and 116:
115 abduCtor teNdoN problemS aFter
Page 117 and 118:
117 reCogNiziNg aNd treatiNg proble
Page 119 and 120:
119 debateS oN CoNtemporary iSSueS
Page 121 and 122:
with custom guides (87.9%) compared
Page 123 and 124:
123 multi-radiuS Femoral kNee geome
Page 125 and 126:
125 high FleXioN deSigN improveS mo
Page 127 and 128:
127 CroSS-liNked polyethyleNe Shoul
Page 129 and 130:
129 CompreheNSive multi-modal paiN
Page 131 and 132:
I. Origins and initial premise Blee
Page 133 and 134:
133 draiNS Should be uSed aFter tka
Page 135 and 136:
Value of Stems in TKA Revision: •
Page 137 and 138:
137 biCoNveX patella For the thiN r
Page 139 and 140:
139 StatiC CemeNt SpaCerS For iNFeC
Page 141 and 142:
141 CurreNt CoNtroverSieS iN partia
Page 143 and 144:
manufacturer. With the utilization
Page 145 and 146:
145 oNlay troChlear CompoNeNt deSig
Page 147 and 148:
oth are great, but lateral uka iS b
Page 149 and 150:
149 triCkS oF the trade to improve
Page 151 and 152:
construed as a guaranteed norm with
Page 153 and 154:
153 FiXed beariNg oNlay iS tried aN
Page 155 and 156:
155 doN’t worry about wear with m
Page 157 and 158:
Risks Risks unique to mobile bearin
Page 159 and 160:
Technique Bone Preparation and Ceme
Page 161 and 162:
Anatomic Challenges: 161 Figure 7:
Page 163 and 164:
163 the aCl deFiCieNt kNee CaN be a
Page 165 and 166:
165 iNtroduCtioN: ligameNtS From bi
Page 167 and 168:
167 the SyNdeSmoSiS: biNdiNg the ti
Page 169 and 170:
169 tendons to reconstruct a. No re
Page 171 and 172:
References: 1. Garrick JG: The freq
Page 173 and 174:
173 a) Expensive b) Doesn’t corre
Page 175 and 176:
TMT joints Anatomy • very stable
Page 177 and 178:
8) Sherief TI, Mucci B, Greiss M. L
Page 179 and 180:
179 the abC’S oF platelet-riCh pl
Page 181 and 182:
181 CliNiCal outComeS uSiNg prp: do
Page 183 and 184:
183 reSearCh For immediate traNSlat
Page 185 and 186:
REFERENCES 185 resulted in increase
Page 187 and 188:
23. Martin JA, Buckwalter JA: Post-
Page 189 and 190:
189 traNSlatioNal reSearCh you CaN
Page 191 and 192:
191 New optioNS iN polymerS aNd Cer
Page 193 and 194:
193 metal oN metal beariNgS aNd bio
Page 195 and 196:
195 aaoS quality iNitiativeS, healt
Page 197 and 198:
197 how the ameriCaN JoiNt replaCem
Page 199 and 200:
199 CurreNt aaoS quality iNitiative
Page 201 and 202:
201 aligNiNg our eFFortS with emplo
Page 203 and 204:
203 evaluatioN oF hoSt NatioN Capab
Page 205 and 206:
IV. Statistics 1. Management of sta
Page 207 and 208:
207 eXtremity vaSCular iNJurieS iN
Page 209 and 210:
209 eXtremity FraCtureS iN aN auSte
Page 211 and 212:
211 short period of time must be co
Page 213 and 214:
irrigation of the intraarticular sp
Page 215 and 216:
215 u boNe deFeCtS: wheN are orthob
Page 217 and 218:
muscle pouches of athymic nude mice
Page 219 and 220:
219 oSteoiNduCtive/oSteopromotive g
Page 221 and 222:
221 traNSplaNtatioN oF autogeNouS o
Page 223 and 224:
223 FraCtureS - aNy Stage From aCut
Page 225 and 226:
16. Muschler GF, Midura MJ. Connect
Page 227 and 228:
orthobiologiCS oF aNterior lumbar i
Page 229 and 230:
229 boNe deFeCtS: wheN are orthobio
Page 231 and 232:
Figure 2B: Pre-op Massive contained
Page 233 and 234:
233 operative FiXatioN oF pediatriC
Page 235 and 236:
— In general, 10-30 degrees of an
Page 237 and 238:
237 b. Dislocation of the radial he
Page 239 and 240:
239 iNtroduCtioN, Summary oF CliNiC
Page 241 and 242:
37. Sun JS, Chang CH, Wu CC, et al:
Page 243 and 244:
6. Peltier LF, Bickel EY, Lillo R,
Page 245 and 246:
3. McQueen MM. Redisplaced unstable
Page 247 and 248:
REFERENCES 247 I. Open Technique Do
Page 249 and 250:
249 CompliCatioNS oF diStal radiuS
Page 251 and 252:
4. Very poor hand function (e.g. ch
Page 253 and 254:
253 u adult CoNSequeNCeS oF pediatr
Page 255 and 256:
255 poor long- term outcome. Acetab
Page 257 and 258:
References 257 c. Surgical Options
Page 259 and 260:
i. Intrasubstance ACL injuries in c
Page 261 and 262:
261 leg-leNgth diSCrepaNCy aNd blou
Page 263 and 264:
263 upper eXtremity FraCtureS aNd C
Page 265 and 266:
265 SympoSium z: aCl reCoNStruCtioN
Page 267 and 268:
267 youth SportS: dramatiC ChaNgeS,
Page 269 and 270:
269 u The FDA has not cleared the d
Page 271 and 272:
(Donaldson 2008) — 20 OCD lesions
Page 273 and 274:
30. Emmerson BC, Gšrtz S, Jamali A
Page 275 and 276:
275 — Type 1 - Younger athlete -
Page 277 and 278:
277 — average follow-up = 2.9 yrs
Page 279 and 280:
6. Blogging 7. RSS feeds 8. Social
Page 281 and 282:
281 hoSpital-baSed employmeNt oF or
Page 283 and 284:
283 hoSpital-baSed employmeNt oF or
Page 285 and 286:
• Aligned Mission and Philosophy
Page 287 and 288:
4. American Academy of Orthopaedic
Page 289 and 290:
289 healthCare reForm bill: paSt, p
Page 291 and 292:
291 the aaoS perSpeCtive oN the ppa
Page 293 and 294:
293 emr: maNdatory CompoNeNtS aNd e
Page 295 and 296:
295 ARRA “Stimulus Stimulus Bil
Page 297 and 298:
297 Prom ote Utilization How How d
Page 299 and 300:
299 Hardware Issues Hardware glitc
Page 301 and 302:
301 Meaningful Use: How to get the
Page 303 and 304:
303 NCCI/G SC/COPN NCCI - Nationa
Page 305 and 306:
305 Know if You are Subm itting Cla
Page 307 and 308:
307 NEW PATIENT VISIT Patient Fo
Page 309 and 310:
309 Orthopedic Exam = TRIM T - Ten
Page 311 and 312:
311 Established EstablishedPatient
Page 313 and 314:
A. The Legal Environment 1. Recover
Page 315 and 316:
315 CORE SET - Eligible Professiona
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
321 meaSuriNg value iN orthopaediCS
Page 323 and 324:
323 start by meeting the needs of l
Page 325 and 326:
325 Baseline 3 mos 6mos 1yr 2yrs 5)
Page 327 and 328:
327 CoSt-eFFeCtiveNeSS aNalySiS iN
Page 329 and 330:
variation in the ED-5D at each foll
Page 331 and 332:
331 meaSuriNg value iN orthopaediCS
Page 333 and 334:
333 the elephaNt iN the liviNg room
Page 335 and 336:
335 psychological distress, and ret
Page 337 and 338:
REFERENCES 1. Goffman E. Stigma: No
Page 339 and 340:
339 Obese patients inactive after T
Page 341 and 342:
341 Telephone support for TKR: Join
Page 343 and 344:
ood/excellent •Improved Physical
Page 345 and 346:
• MCS50 - BDI= 6.4 345 0 =50 BECK
Page 347 and 348:
347 aC JoiNt iNJurieS: wheN Should
Page 349 and 350:
349 rotator CuFF repair iN 2011 - d
Page 351 and 352:
harmed. Prolonged cases, trying to
Page 353 and 354:
3. Can be done arthroscopically by
Page 355 and 356:
3. Hill JM, McGuire MH, Crosby L
Page 357 and 358:
357 the gold StaNdard—all polyeth
Page 359 and 360:
I. Disclosures 359 biologiC replaCe
Page 361 and 362:
361 the gold StaNdard - Stemmed hum
Page 363 and 364:
7. Gartsman, G. M.; Roddey, T. S.;
Page 365 and 366:
365 reverSe Shoulder arthroplaSty F
Page 367 and 368:
367 the gold StaNdard radiographiC
Page 369 and 370:
Figure 2. Typical navigational comp
Page 371 and 372:
371 leSS iNvaSive Shoulder arthropl
Page 373 and 374:
373 i. The long-term clinical signi
Page 375 and 376:
375 oCCipitoCerviCal iNJurieS iNClu
Page 377 and 378:
maintaining a low profile. The most
Page 379 and 380:
of 161 patients undergoing transart
Page 381 and 382:
failure in the cervical spine witho
Page 383 and 384:
on the inner skull behind the super
Page 385 and 386:
385 CerviCal SpiNe trauma: SubaXial
Page 387 and 388:
Cervicothoracic Trauma Objectives:
Page 389 and 390:
389 u SpiNal deFormity: what every
Page 391 and 392:
391 1. Asssessment of hip/knee cont
Page 393 and 394:
393 deformity. vii)EOS managed with
Page 395 and 396:
BIBLIOGRAPHY 395 1. PSF w/instrumen
Page 397 and 398:
6. Nozawa S Wire repair of spondylo
Page 399 and 400:
3. Health and function of patients
Page 401 and 402:
1. Overview a. Classification b. Pr
Page 403 and 404:
403 IV. Acromioclavicular Joint Joh
Page 405 and 406:
405 Applicability: What is also inf
Page 407 and 408:
19. Mologne TS, Provencher MT, Menz
Page 409 and 410:
• At 3 months, advance strengthen
Page 411 and 412:
411 1. Characteristics Types 1-IV a
Page 413 and 414:
16. Stetson, WB, Snyder,SJ, Karzel,
Page 415 and 416:
415 Study JNL/ Year Study details O
Page 417 and 418:
Anatomy & Biomechanics • The knee
Page 419 and 420:
419 - Late Chondrosis (MFC and Pate
Page 421 and 422:
Order of Graft Passage/Fixation •
Page 423 and 424:
Rotational Moment Fibular-Based Rec
Page 425 and 426:
425 CompliCatioNS oF multiligameNto
Page 427 and 428:
• Initial management includes pro
Page 429 and 430:
429 orthopaediC trauma mythbuSterS
Page 431 and 432:
431 myth: CalCaNeuS FraCtureS: NoNo
Page 433 and 434:
18. Muschler GF, Midura MJ. Connect
Page 435 and 436:
435 myth: limb Salvage iS better th
Page 437 and 438:
437 myth: hip diSloCatioNS: timiNg
Page 439 and 440:
439 imagiNg iN muSCuloSkeletal tumo
Page 441 and 442:
The ability to interpret lesions of
Page 443 and 444:
• Demographics — Benign soft ti
Page 445 and 446:
PAPERS 445 adult reconstruction hiP
Page 447 and 448:
equired for a THA. The amount of ac
Page 449 and 450:
pApeR No. 044 Topographical Cartila
Page 451 and 452:
pApeR No. 065 Inflammatory Cytokine
Page 453 and 454:
pApeR No. 071 Large Diameter Modula
Page 455 and 456:
fracture of the prosthesis. Six pat
Page 457 and 458:
pApeR No. 189 Revision Hip Arthropl
Page 459 and 460:
Type IV impingement, Type V late we
Page 461 and 462:
of this modular proximal hydroxyapa
Page 463 and 464:
age, gender, cost of implant, lengt
Page 465 and 466:
pApeR No. 470 Does Vitamin E Addict
Page 467 and 468:
pApeR No. 476 Does Bridging With Lo
Page 469 and 470:
edge loading occurs with the hip fl
Page 471 and 472:
three years would show no differenc
Page 473 and 474:
pApeR No. 706 Correlation Between R
Page 475 and 476:
of the fractured components was sim
Page 477 and 478:
abstracted from the medical records
Page 479 and 480:
and 202 (range 23-563) days, respec
Page 481 and 482:
width and head/neck ratio, a smalle
Page 483 and 484:
without mechanical symptoms. We per
Page 485 and 486:
posteR No. p024 Wear and Surface Da
Page 487 and 488:
and required staged revision and tw
Page 489 and 490:
posteR No. p037 The Value Of Three-
Page 491 and 492:
posteR No. p044 Acetabular Alignmen
Page 493 and 494:
posteR No. p051 Peripheral Blood St
Page 495 and 496:
loosening with a rate of 57.1% (44/
Page 497 and 498:
were found for intraobserver reliab
Page 499 and 500:
developed at our institution specif
Page 501 and 502:
(14%) than in hips that received li
Page 503 and 504:
of peroxides were lower in the semi
Page 505 and 506:
posteR No. p089 In vivo Oxidation O
Page 507 and 508:
Mann-Whitney-Test. The test was two
Page 509 and 510:
prealbumin and TLC and increased C-
Page 511 and 512:
posteR No. p108 Endoscopic Illiopso
Page 513 and 514:
and location of fractures were reco
Page 515 and 516:
surgical treatment for PJI remain l
Page 517 and 518:
good surgical technique with select
Page 519 and 520:
At minimum 20-year follow up, 20 pa
Page 521 and 522:
height and posterior slope of the p
Page 523 and 524:
pApeR No. 121 Pre-Admission Chlorhe
Page 525 and 526:
surgical wound infection. A total o
Page 527 and 528:
pApeR No. 134 Variable Cartilage De
Page 529 and 530:
in 13, loosening in 10 and wear-ost
Page 531 and 532:
tibial component. An extensive lite
Page 533 and 534:
pApeR No. 291 Benefits of Prolonged
Page 535 and 536:
knee score mean was 86 at last foll
Page 537 and 538:
pApeR No. 409 An RCT Comparing Fixe
Page 539 and 540:
715 patients (13.2%) were recurvatu
Page 541 and 542:
performed MDCT scans on 48 consecut
Page 543 and 544:
pApeR No. 596 Early Failure of Post
Page 545 and 546:
1999 and 2009, 276 consecutive medi
Page 547 and 548:
posteR No. p120 UKA after Spontaneo
Page 549 and 550:
average 9.5 degrees (p=0.04). Six c
Page 551 and 552:
2007. HTO was almost exclusively us
Page 553 and 554:
clinical infection was 15.5 months
Page 555 and 556:
prophylaxis attempting to maintain
Page 557 and 558:
A control activity dataset was coll
Page 559 and 560:
posteR No. p161 Incidence, Predicto
Page 561 and 562:
posteR No. p167 Navigation Does Not
Page 563 and 564:
adiographs were reviewed for signs
Page 565 and 566:
posteR No. p180 Bacterial Contamina
Page 567 and 568:
(within 40 days), acute hematogenou
Page 569 and 570:
posteR No. p193 Computer Assisted T
Page 571 and 572:
in 70.5% (12/17) GN compared to 78.
Page 573 and 574:
or more components had to be cement
Page 575 and 576:
scieNtific exHibit No. se20 Customi
Page 577 and 578:
(8.23±0.51m/s2 vs 8.56±0.34m/s2,
Page 579 and 580:
SCIENTIFIC EXHIBITS scieNtific exHi
Page 581 and 582:
PAPERS pApeR No. 046 Treatment of T
Page 583 and 584:
three study groups. The mean reacti
Page 585 and 586:
pApeR No. 060 Complications and Reo
Page 587 and 588:
S1 with that of S2. From 1991 to 20
Page 589 and 590:
statistically significant (p = 0.31
Page 591 and 592:
pApeR No. 498 Plantar Pressure Anal
Page 593 and 594:
warranted PSB as anesthesia for foo
Page 595 and 596:
to 20.1°±3.6 (p
Page 597 and 598:
scale and Sefton grading system. Th
Page 599 and 600:
grafting procedures for lesions ove
Page 601 and 602:
educing forefoot pain, but the lite
Page 603 and 604:
PAPERS pApeR No. 271 The Use of Sod
Page 605 and 606:
pApeR No. 277 Thumb Deformity In Pa
Page 607 and 608:
phalangeal joint significantly impr
Page 609 and 610:
pApeR No. 335 Bone Cement Augmentat
Page 611 and 612:
or resection arthroplasty of the di
Page 613 and 614:
examined, 13 patients had normal th
Page 615 and 616:
pApeR No. 566 Contribution of Flexo
Page 617 and 618:
quadrant is a feature of functional
Page 619 and 620:
posteR No. p236 AlteRNAte pApeR Hig
Page 621 and 622:
disease detectable by MRI. Medline
Page 623 and 624:
pApeR No. 169 Significant Rate of M
Page 625 and 626:
pApeR No. 175 The Location of the M
Page 627 and 628:
hooks plowed intra-operatively resu
Page 629 and 630:
pApeR No. 398 Significant Differenc
Page 631 and 632:
special interest was the frequency
Page 633 and 634:
patients by CPT code having foot ar
Page 635 and 636:
pApeR No. 431 Pathologic Fractures
Page 637 and 638:
on 3T machine at baseline and one-y
Page 639 and 640:
pApeR No. 549 uOutcomes of Minimall
Page 641 and 642:
In the developmental cases, three (
Page 643 and 644:
treated 479 total fractures (23 per
Page 645 and 646:
sedate rapid sequence MRI within 24
Page 647 and 648:
the majority of patients (70.4%). T
Page 649 and 650:
the functionality of the shoulder,
Page 651 and 652:
y non-operative fracture care. We t
Page 653 and 654:
treatment recommendations requires
Page 655 and 656:
completed the survey. Some 49% (292
Page 657 and 658:
There were 16 male and 49 female pa
Page 659 and 660:
also analyzed. Seventeen cases were
Page 661 and 662:
posteR No. p275 Developing a New Pr
Page 663 and 664:
Standards of Professionalism. scieN
Page 665 and 666:
pApeR No. 619 Iliopsoas Muscle Atro
Page 667 and 668:
and 36 professional) with a mean ag
Page 669 and 670:
posteR No. p277 Effectiveness of a
Page 671 and 672:
of families would treat a second ch
Page 673 and 674:
clinical and radiological outcomes.
Page 675 and 676:
value (SSV) was 77%. All patients w
Page 677 and 678:
week in steroid groups (IS, TS) com
Page 679 and 680:
cuff is much simpler that with mini
Page 681 and 682:
compare the functional results of h
Page 683 and 684:
at an implant price below $14,875,
Page 685 and 686:
the positive effect of injection on
Page 687 and 688:
pApeR No. 605 Efficacy Of Different
Page 689 and 690:
the community radiologists (p
Page 691 and 692:
pApeR No. 678 1 vs. 2 Incision Tech
Page 693 and 694:
0.14°±7.08° in extension and 0.5
Page 695 and 696:
POSTERS posteR No. p286 Radial Nerv
Page 697 and 698:
posteR No. p293 Radiocapitellar Pre
Page 699 and 700:
0.51, 0.39 and 0.6, respectively. C
Page 701 and 702:
significant improvement of their cl
Page 703 and 704:
posteR No. p313 Diagnostic Performa
Page 705 and 706:
posteR No. p319 Effectiveness of Ph
Page 707 and 708:
and internal rotation were also sim
Page 709 and 710:
posteR No. p331 Natural History Of
Page 711 and 712:
(HHA) and partial resurfacing arthr
Page 713 and 714:
outcomes following HHR for four-par
Page 715 and 716:
scieNtific exHibit No. se52 Salvage
Page 717 and 718:
PAPERS pApeR No. 016 Efficacy of Mu
Page 719 and 720:
with or without T2 spinal cord sign
Page 721 and 722:
or 3/3 mm), but the rest allowed on
Page 723 and 724:
and abnormal motion or mobile spond
Page 725 and 726:
controversy remains as to whether t
Page 727 and 728:
pApeR No. 436 Assessment of Factors
Page 729 and 730:
outcomes changes for the following
Page 731 and 732:
fusion levels utilizing the PA and
Page 733 and 734:
hBMP-7 was associated with a smalle
Page 735 and 736:
pApeR No. 670 uThe Effects of Cemen
Page 737 and 738:
pApeR No. 736 Lessons Learned After
Page 739 and 740:
pApeR No. 742 Effect of Methylpredn
Page 741 and 742:
lytic spondylolisthesis, lumbar fus
Page 743 and 744:
level fusions and 19 two-level fusi
Page 745 and 746:
posteR No. p356 Does the Rotation o
Page 747 and 748:
of cervical trauma with concern for
Page 749 and 750:
implant’s inherent stability and
Page 751 and 752:
Additionally, the footprint of the
Page 753 and 754:
heterotopic bone in the canal or ne
Page 755 and 756:
lack of significant differences in
Page 757 and 758:
mean operative time and ICU stay. C
Page 759 and 760:
levels were C2-3 and C3-4. Twenty-s
Page 761 and 762:
professionals. and sponsor spine co
Page 763 and 764:
PAPERS 763 sPorts Medicine and arth
Page 765 and 766:
pApeR No. 203 Long-Term Assessment
Page 767 and 768:
pApeR No. 209 Supraphysiological Te
Page 769 and 770:
laxity was measured before and afte
Page 771 and 772:
absent in 92%. Insall-salvati ratio
Page 773 and 774:
ACL origin to the popliteal inserti
Page 775 and 776:
the mean side-to-side difference in
Page 777 and 778:
pApeR No. 571 Treatment Of Shoulder
Page 779 and 780:
pApeR No. 577 The Effect of Platele
Page 781 and 782:
pApeR No. 584 Does the Remplissage
Page 783 and 784:
measured using CT and MRI. The aver
Page 785 and 786:
epair group (p
Page 787 and 788:
pApeR No. 650 Risk of Acute Compart
Page 789 and 790:
two post-procedure through routine
Page 791 and 792:
evaluation of rotational instabilit
Page 793 and 794:
36 (p=0.0259 for PHI and p=0.0036 f
Page 795 and 796:
posteR No. p421 Intercondylar Notch
Page 797 and 798:
Hill-Sachs size across multiple sco
Page 799 and 800:
posteR No. p433 Outcomes of Meniscu
Page 801 and 802:
posteR No. p440 AlteRNAte pApeR Sur
Page 803 and 804:
posteR No. p447 Patellar Tendon Bon
Page 805 and 806:
posteR No. p454 Hip Arthroscopy for
Page 807 and 808:
a minimum two year follow-up. This
Page 809 and 810:
scieNtific exHibit No. se72 Practic
Page 811 and 812:
pApeR No. 139 Sorted Mesenchymal St
Page 813 and 814:
in the adult patient exposed to blu
Page 815 and 816:
pApeR No. 212 Complication Risk fol
Page 817 and 818:
failure in the reduced (r = 0.76, p
Page 819 and 820:
pApeR No. 225 Are Conventional Inle
Page 821 and 822:
pApeR No. 306 A Biomechanical Analy
Page 823 and 824:
pApeR No. 312 Location of Gunshot W
Page 825 and 826:
pApeR No. 378 Comparison of Five Pr
Page 827 and 828:
were included in this prospectively
Page 829 and 830:
pApeR No. 692 uPRCT of Subacromial
Page 831 and 832:
pApeR No. 699 Internal vs External
Page 833 and 834:
A) and 100 Burgess combat-related t
Page 835 and 836:
Three patients had positive blood c
Page 837 and 838:
morbidities to the affected limb an
Page 839 and 840:
posteR No. p457 The Impact of Morbi
Page 841 and 842:
1997-2007. Patients were reviewed f
Page 843 and 844:
through an institutional fracture d
Page 845 and 846:
(460 out of 7,349), and with osteon
Page 847 and 848:
posteR No. p483 Dynamization of the
Page 849 and 850:
clean orthopaedic surgery with the
Page 851 and 852:
posteR No. p498 Fate of Combat Nerv
Page 853 and 854:
flexion contracture (p=0.001) and f
Page 855 and 856:
data when known were similar to pri
Page 857 and 858:
initially with ORIF went on to deve
Page 859 and 860:
Research Society (ORS) bring togeth
Page 861 and 862:
PAPERS 861 tuMor and Metabolic dise
Page 863 and 864:
pApeR No. 232 A High Serum Levels O
Page 865 and 866:
enhanced OC formation in monocyte c
Page 867 and 868:
pApeR No. 515 Impact of Close Surgi
Page 869 and 870:
disease, eight cases of limb deform
Page 871 and 872:
of histologic tumor necrosis betwee
Page 873 and 874:
Future prospective studies are need
Page 875 and 876:
Interobserver consistency of two se
Page 877 and 878:
posteR No. p540 Radiological Evalua
Page 879 and 880:
posteR No. p565 The Local Treatment
Page 881 and 882:
14-57) were acutely corrected, and
Page 883 and 884:
MEC05 Anterior Hip Arthroplasty App
Page 885 and 886:
in details the use of the software
Page 887 and 888:
plate is that it facilitates proper
Page 889 and 890:
technique in which we use cerclage
Page 891 and 892:
an alternative graft choice for ana
Page 893 and 894:
followed by reconstruction with a m
Page 895 and 896:
NAME AAOS EVENT NAME AAOS EVENT And
Page 897 and 898:
NAME AAOS EVENT NAME AAOS EVENT Ber
Page 899 and 900:
NAME AAOS EVENT NAME AAOS EVENT Cac
Page 901 and 902:
NAME AAOS EVENT NAME AAOS EVENT Coo
Page 903 and 904:
NAME AAOS EVENT NAME AAOS EVENT Dou
Page 905 and 906:
NAME AAOS EVENT NAME AAOS EVENT Fre
Page 907 and 908:
NAME AAOS EVENT NAME AAOS EVENT Gru
Page 909 and 910:
NAME AAOS EVENT NAME AAOS EVENT Hol
Page 911 and 912:
NAME AAOS EVENT NAME AAOS EVENT Ju,
Page 913 and 914:
NAME AAOS EVENT NAME AAOS EVENT Ko,
Page 915 and 916:
NAME AAOS EVENT NAME AAOS EVENT Leo
Page 917 and 918:
NAME AAOS EVENT NAME AAOS EVENT Mas
Page 919 and 920:
NAME AAOS EVENT NAME AAOS EVENT Mor
Page 921 and 922:
NAME AAOS EVENT NAME AAOS EVENT Ome
Page 923 and 924:
NAME AAOS EVENT NAME AAOS EVENT Pol
Page 925 and 926:
NAME AAOS EVENT NAME AAOS EVENT Rus
Page 927 and 928:
NAME AAOS EVENT NAME AAOS EVENT Shi
Page 929 and 930:
NAME AAOS EVENT NAME AAOS EVENT Tak
Page 931 and 932:
NAME AAOS EVENT NAME AAOS EVENT Var
Page 933 and 934:
NAME AAOS EVENT NAME AAOS EVENT Wol
Page 935 and 936:
KEYWORD AAOS EVENT KEYWORD AAOS EVE
Page 937 and 938:
Page 939 and 940:
show all

Annual Meeting Proceedings - American Academy of Orthopaedic ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?